A recent tragedy in Scotland has raised concerns over the safety of the weight loss drug tirzepatide. Susan McGowan, a 58-year-old nurse from North Lanarkshire, passed away from multiple organ failure and pancreatitis shortly after taking the NHS-approved drug. Her death, which occurred on September 4, is the first in the UK officially linked to tirzepatide.

Tirzepatide, branded as Mounjaro, was initially developed for type 2 diabetes but was later approved for weight loss treatment. The drug works by mimicking hormones that signal fullness, helping users eat less. It costs between £150 and £200 for a four-week supply, making it an affordable option for those struggling with obesity.

However, Susan’s sudden decline after taking the drug highlights the potential risks. After her second low-dose injection, she experienced severe stomach pain and nausea, leading to her eventual organ failure. This incident has raised questions about the drug’s safety, particularly for those without diabetes.

As tirzepatide continues to be prescribed for weight loss, patients are advised to consult healthcare providers, report any side effects, and undergo regular monitoring to ensure safety.